Valuation: Lexicon Pharmaceuticals, Inc.

Market Cap 1.1B 951M 888M 814M 1.53B 105B 1.56B 10.42B 4.09B 52.43B 4.13B 4.04B 173B P/E 2026 *
-13.4x
P/E 2027 * -13x
Enterprise Value 1.1B 951M 888M 814M 1.53B 105B 1.56B 10.42B 4.09B 52.43B 4.13B 4.04B 173B EV / Sales 2026 *
32.6x
EV / Sales 2027 * 55.2x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 day+4.66%
1 week+6.93%
Current month+6.93%
1 month+8.81%
3 months+23.50%
6 months+100.81%
Current year+114.78%
1 week 1.96
Extreme 1.96
2.52
1 month 1.96
Extreme 1.96
2.52
Current year 1.1
Extreme 1.1
2.68
1 year 1.02
Extreme 1.02
2.68
3 years 0.28
Extreme 0.2836
3.73
5 years 0.28
Extreme 0.2836
6.33
10 years 0.28
Extreme 0.2836
19.62
Manager TitleAgeSince
Chief Executive Officer 56 08/07/2024
Director of Finance/CFO 59 02/01/2025
Chief Tech/Sci/R&D Officer - 01/02/2025
Director TitleAgeSince
Chairman 83 01/01/2005
Chairman 71 27/02/2012
Director/Board Member 67 28/08/2007
Date Insider Type Main position Quantity % Market Cap.
2/28/26 A Fiscal year

Chief Executive Officer

1,211,357 0.3333%
2/28/26 A Fiscal year

Chief Financial Officer

375,355 0.1033%
2/28/26 A Fiscal year

Investor Relations Manager

380,300 0.1047%
Change 5-day change 1-year change 3-year change Capi.($)
+4.66%+6.93%+128.70%+35.71% 1.1B
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +3.93%+11.21%+61.47%+190.43% 26.47B
Weighted average by Cap. +4.36%+13.07%+51.01%+167.92%

Financials

2026 *2027 *
Net sales 33.75M 29.19M 27.26M 25.01M 47.03M 3.21B 47.78M 320M 126M 1.61B 127M 124M 5.32B 19.91M 17.22M 16.09M 14.76M 27.75M 1.9B 28.2M 189M 74.07M 950M 74.78M 73.14M 3.14B
Net income -79.83M -69.05M -64.48M -59.15M -111M -7.6B -113M -757M -297M -3.81B -300M -293M -12.59B -90.89M -78.62M -73.42M -67.35M -127M -8.65B -129M -861M -338M -4.34B -341M -334M -14.33B
Net Debt - -
Logo Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
Employees
81
Date Price Change Volume
07/08/26 $2.470 +4.66% 3,085,741
06/08/26 $2.360 -3.67% 4,890,832
05/08/26 $2.450 -1.61% 3,974,293
04/08/26 $2.490 +6.87% 3,908,893
03/08/26 $2.330 +0.87% 2,053,054
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
2.470USD
Average target price
3.856USD
Spread / Average Target
+56.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXRX Stock